<DOC>
	<DOCNO>NCT03063879</DOCNO>
	<brief_summary>Sofosbuvir base treatment regimens hepatitis C. In patient renal failure blood level one metabolites ( GS-331007 ) rise 20 fold . Although particular adverse event link metabolite sofosbuvir recommend patient renal failure mainly lack data . Nevertheless anecdotal report small study prove safety sofosbuvir renal failure . This study address lack information evaluate safety eficacy sofosbuvir daclatasvir treat hepatitis C 100 patient renal failure .</brief_summary>
	<brief_title>Treating HCV CRF Using Sofosbuvir Daclatasvir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Positive qualitative HCV RNA test two occasion least 6 month apart Renal failure ( eGFR &gt; 30 cc/min ) MELD score &gt; 20 , Child 's C ( CTP score &gt; 12 ) , Heart rate &lt; 50/min , Taking amiodarone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>renal failure</keyword>
	<keyword>sofosbuvir</keyword>
	<keyword>daclatasvir</keyword>
</DOC>